Main content

    Stroke / Neuro Critical Care

    Comprehensive Stroke CareOpens new window | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: Expanding the Time Window for IV Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Using Computed Tomography Perfusion Imaging: The PERFusion Use in Stroke Evaluation (PERFUSE) Study
    Description: Patients with ischemic stroke who can be treated within six hours of symptom onset
    Investigator: Nobl Barazangi, MD
    Eligibility: Acute Ischemic Stroke (AIS) patients, ≥ 18 years old, who present up to 6 hours from time of onset of acute stroke symptoms
    Status: Active and open to enrollment
    Contact: Katie Ponting, 415-600-1163, Email: PontinK@cpmcri.org about Study PERFUSE

    Title: COMPASS Trial: a Direct Aspiration First Pass Technique
    Description: This is a prospective, randomized trial comparing mechanical thrombectomy with the ADAPT approach to stent retrievers in patients presenting with AIS within 6 hours of symptom onset
    Investigator: Joey English, MD
    Eligibility: Subjects, 18 y/o and older, with acute ischemic stroke, NIHSS ≥8 at the time of neuroimaging and persistent symptoms within 6 hours of when groin puncture can be obtained
    Status: Active and open to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study COMPASS

    Title: RAGE is a prospective, non-randomized, multicenter, post-market study. The RAGE study is designed to determine the safety and occlusion rates of hydrogel coils in the ruptured aneurysm study population. Secondary objectives include determining clinical outcomes, packing density, occlusion stability, rates of recurrence, rebleed, retreatment, and adverse events.
    Description: The RAGE study is designed to determine the safety and occlusion rates of hydrogel coils in the ruptured aneurysm study population. Secondary objectives include determining clinical outcomes, packing density, occlusion stability, rates of recurrence, rebleed, retreatment, and adverse events.
    Investigator: Nich Telischak M.D.
    Eligibility: 18 years to 75 years
    Status: Open to Enrollment
    Contact: Email: rossd1@sutterhealth.org about the RAGE Stroke Study

    Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
    Description: The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization.
    Investigator: Nobl Barazangi M.D. & Joey English M.D.
    Eligibility: 18 years and older
    Status: Open to Enrollment
    Contact: Email: rossd1@sutterhealth.org about the ESCAPE-NA-1 Stroke Study

    Updated April 2018
    Back to top